Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | ZL-1310 |
Synonyms | |
Therapy Description |
ZL-1310 is an antibody-drug conjugate (ADC) comprising an antibody targeting DLL3 linked to a camptothecin derivative, which potentially inhibits tumor growth (ESMO Open, Volume 9, 102891). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
ZL-1310 | ZL1310|ZL 1310|YL212|YL 212|YL-212|ADC SC-002 | DLL3 Antibody 6 | ZL-1310 is an antibody-drug conjugate (ADC) comprising an antibody targeting DLL3 linked to a camptothecin derivative, which potentially inhibits tumor growth (ESMO Open, Volume 9, 102891). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT06179069 | Phase I | ZL-1310 | An Open-label, Multicenter Study of ZL-1310 in Subjects With Small Cell Lung Cancer | Recruiting | USA | 1 |